Otsuka America Pharmaceutical, Inc.

Otsuka America Pharmaceutical, Inc. Otsuka is a healthcare company driven by our purpose and defined by our beliefs. At Otsuka, we hold a deep respect for the value of every mind. residents only.

We believe that the human mind is infinitely valuable, fostering imagination, intelligence, perception, and so much more. By recognizing this value, we have the power to change the trajectory of people’s lives. This is why we will not rest until mental illnesses and brain diseases are approached with the same priority and urgency as our physical health and recognized as chronic diseases that warra

nt early, equitable, and accessible intervention. Through products, programs, policies, and advocacy, Otsuka-people will defy any limitation that stands in their way until every mind is valued. This commitment extends to those who care for people living with mental illnesses and other brain conditions. We are dedicated to caring for those who care for our patients—standing with them, the way they stand with their loved ones—and offering the tools they need for the health of others and themselves

----
There are two Otsuka pharmaceutical industry companies in the U.S.:

Otsuka America Pharmaceutical, Inc. (OAPI) successfully commercializes Otsuka-discovered and in-licensed products in North America. Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) clinically develops and registers innovative healthcare products on a global basis

Learn more at www.otsuka-us.com

----
Community Guidelines:

Welcome to the Otsuka page. We're excited to have you be part of our Facebook community, and look forward to discussing a variety of topics. However, we'd like to remind you that healthcare is a regulated industry and, as such, we cannot engage in discussions about our products – or the products of other companies. With this in mind, we may not be able to respond to or comments that:
Mention products
Include profanity, defamatory or abusive comments
Offer health or medical advice
Are spam or are soliciting business
Violate Facebook's platform rules

Please keep in mind that this page is intended for U.S. Also, please note that Facebook accounts that the Otsuka handle follows, or are followed by, are not an indication of an endorsement by Otsuka feeds or the content they produce. With this in mind, comments made on third party feeds that the Otsuka handle follows do not necessarily represent the opinion of Otsuka America Pharmaceutical, Inc., or Otsuka Pharmaceutic Development & Commercialization, Inc. Medical Side Effects or Adverse Events
If you believe that you have experienced any medical side effects or reactions from an Otsuka product, you should consult your physician, pharmacist or other healthcare professional immediately. If you wish to report an adverse event associated with any of our products, please call us at 1-800-438-9927. The FDA also has a website where you can report side effects of prescription drugs at www.fda.gov/medwatch, or call 1-800-FDA-1088.

We are feeling energized after our time spent with mental health clinicians at the Psych Congress Elevate earlier this m...
06/22/2026

We are feeling energized after our time spent with mental health clinicians at the Psych Congress Elevate earlier this month.

At Otsuka, we will not rest until mental illnesses and brain diseases are approached with the same priority and urgency as our physical health and recognized as chronic diseases that warrant early, equitable, and accessible intervention.

Discover our commitment at www.otsuka-us.com/CNS​

Otsuka is a proud sponsor of Psych Congress Elevate.

June is Men's Health Month, a month dedicated to the awareness of preventable health problems, encourage early detection...
06/17/2026

June is Men's Health Month, a month dedicated to the awareness of preventable health problems, encourage early detection/treatment of diseases, and promote healthy lifestyles for men.

With a higher percentage of males affected, we are committed to raising awareness of Immunoglobulin A Nephropathy (IgA Nephropathy), a progressive, autoimmune, chronic kidney disease that typically manifests in adults aged 20-40 years and leads to end-stage kidney disease (ESKD) within the lifetime of most patients.

Talk to your healthcare professional today if you are experiencing any symptoms of IgA Nephropathy.

Learn more about our commitment: www.otsuka-us.com/nephrology

 : Today, Otsuka America, Inc., a subsidiary of Otsuka Pharmaceutical Co., Ltd. has completed the acquisition of Transce...
06/12/2026

: Today, Otsuka America, Inc., a subsidiary of Otsuka Pharmaceutical Co., Ltd. has completed the acquisition of Transcend Therapeutics, Inc., a clinical-stage biotechnology company developing a rapid-acting treatment for post-traumatic stress disorder (PTSD).

Read more: https://otsuka-us.com/news/otsuka-completes-acquisition-transcend-therapeutics-advance-next-generation-neuropsychiatric

At Otsuka, our core values of perseverance, unconventional thinking and humility position us to lead in the development of the transformative potential of innovative therapies in mental healthcare.

06/09/2026

We are honored to announce our placement on 2026 Fortune Best Workplaces in New York™ 2026 List.

Otsuka Pharmaceutical Companies (U.S.) is a healthcare company made up of motivated individuals—people who share the mission to create new products for better health worldwide. We live by our purpose: defy limitation, so that others can too.

Read more now: https://www.greatplacetowork.com/best-workplaces/new-york/2026

06/09/2026

This Pride Month, Otsuka acknowledges the courage and resilience of all those who have paved the way for greater acceptance and inclusivity to enable a world where everyone feels they can be their authentic selves.

Otsuka has a rich culture of inclusion and belonging and we are grateful for the experiences and perspectives all Otsuka-people contribute in support of our mission to defy limitation so that others can too.

06/04/2026

: Today, at the European Renal Association (ERA) Congress 2026, we presented positive interim Phase 3 VISIONARY eGFR data for adults with primary IgA nephropathy ( ) at risk for disease progression.

Read more: https://www.otsuka-us.com/news/otsuka-presents-positive-interim-phase-3-visionary-egfr-data-showing-voyxactr-sibeprenlimab

At Otsuka, our continued work is fueled by a relentless curiosity and a goal to provide the most advanced care for patient populations with high unmet needs.

06/02/2026

We understand the pressing unmet need for access to innovative therapeutic solutions in the healthcare of patients with CNS conditions, including mental health disorders like post-traumatic stress disorder.

There is no one-size-fits all approach. ​

We will continue to leverage our extensive footprint in neuroscience and mental health to relentlessly pursue the research and development of new therapeutics.​

Discover our commitment: www.otsuka-us.com/cns

06/01/2026

Our US medical team is thrilled to attend the 63rd European Renal Association (ERA) Congress 2026 and look forward to meeting kidney professionals from across the world.

At Otsuka, our perseverance and long-term commitment to innovation in Nephrology has led to major breakthroughs, giving patients renewed hope and clinicians more options than ever before.

Otsuka is proud to join ERA as a sponsor. Only registered participants of the ERA Congress are eligible to attend as determined by the event organizer, ERA. Otsuka has no control over registration, or the fees associated.

05/28/2026

Today, we are pleased to announce that Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) presented new post hoc, exploratory analyses from Phase 3 clinical trials evaluating centanafadine, an investigational norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI).

Learn more: https://www.otsuka-us.com/news/otsuka-presents-new-phase-3-post-hoc-analyses-centanafadine-highlighting-improvement-executive

At Otsuka, we will not rest until mental illnesses and brain diseases are approached with the same priority and urgency as our physical health and recognized as chronic diseases that warrant early, equitable, and accessible intervention.

05/27/2026

May is Mental Health Awareness Month, a time to reflect on what meaningful progress could look like for people living with CNS conditions in the decade ahead.​

This month, we’re spotlighting perspectives from our leaders on innovation, the importance of continued investment, and the greatest opportunities ahead in mental healthcare.​

From personal motivations to professional insights, these conversations highlight a shared commitment to advancing care, and Otsuka's five decades of leadership in CNS research. ​

Thanks to Thomas Thompson for sharing your perspective with us. ​

At Otsuka, our core values of perseverance, unconventional thinking and humility position us to lead in the development of the transformative potential of innovative therapies in mental healthcare. ​

Discover our commitment: www.otsuka-us.com/CNS

Address

508 Carnegie Center
Princeton, NJ
08540

Alerts

Be the first to know and let us send you an email when Otsuka America Pharmaceutical, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share